Coherus Oncology, Inc. logo CHRS - Coherus Oncology, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 14
HOLD 3
SELL 0
STRONG
SELL 0
| PRICE TARGET: $6.02 DETAILS
HIGH: $11.00
LOW: $1.05
MEDIAN: $6.00
CONSENSUS: $6.02
UPSIDE: 508.08%

Stock News

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development program evaluating the cytolytic CCR8 antibody with toripalimab and multiple solid tumors on Wednesday, October 28, 2026. Coherus management will host a webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to discuss the data and provide additional context. The company has invited key opinion leaders to join the webcast and provide their clinical perspective.

Oct 14, 2026 12:30 PM • globenewswire.com
Comparing Coherus Oncology (NASDAQ:CHRS) and Molecular Partners (NASDAQ:MOLN)

Comparing Coherus Oncology (NASDAQ:CHRS) and Molecular Partners (NASDAQ:MOLN)

Molecular Partners (NASDAQ: MOLN - Get Free Report) and Coherus Oncology (NASDAQ: CHRS - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Earnings and Valuation This table compares Molecular

Oct 04, 2026 11:00 PM • defenseworld.net
Contrasting Emergent Biosolutions (NYSE:EBS) and Coherus Oncology (NASDAQ:CHRS)

Contrasting Emergent Biosolutions (NYSE:EBS) and Coherus Oncology (NASDAQ:CHRS)

Coherus Oncology (NASDAQ: CHRS - Get Free Report) and Emergent Biosolutions (NYSE: EBS - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a breakdown of

Sep 28, 2026 12:15 AM • defenseworld.net
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis to stockholders of record of the Company's common stock as of 5:00 p.m.

Aug 17, 2026 01:33 PM • globenewswire.com
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer – – Projected October public disclosure of data sets with sufficient maturity – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif.

Aug 05, 2026 12:28 PM • globenewswire.com
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026. Starting at 5:00 p.m. Eastern Daylight Time on August 5, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

Jul 22, 2026 09:36 AM • globenewswire.com
Coherus Oncology: Setting Up For Important Readouts In Mid-2026

Coherus Oncology: Setting Up For Important Readouts In Mid-2026

Coherus Oncology (CHRS) remains a Buy as I maintain optimism around its advancing immunotherapy pipeline despite recent market negativity. Key catalysts include mid-2026 data readouts for casdozokitug in HCC and ongoing pivotal JUPITER-02 trial for toripalimab in nasopharyngeal carcinoma. CHRS's liquidity covers 2–3 quarters at current cash burn; further financing may be needed before pivotal clinical milestones.

May 13, 2026 02:00 AM • seekingalpha.com
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug, CCR8 Treg depleter development expands with pharmacological and clinical program differentiation, including dose-responsive immune effects, no off-target binding, acceptable safety – – $167.0 million in quarter-end cash, cash equivalents and marketable securities – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif.

May 11, 2026 12:05 PM • globenewswire.com

Price Targets